Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The Surprising Link Between BRCA Mutations and Prostate Cancer

The Surprising Link Between BRCA Mutations and Prostate Cancer

Scientists have wondered why different cancers develop early in the same individual or family. After an article describing early-onset inherited breast-ovarian cancer appeared in Science in 1990, discoveries followed in 1994 of BRCA1 and in 1995 of BRCA2. As research increased, individuals with damaged forms of these proteins were found to have increased risks not only of breast and ovarian cancer but also pancreatic cancer and, in men, prostate cancer as an additional risk.

The BRCA gene takes its name from the English abbreviation for breast cancer. Proteins called BRCA 1 and 2 repair DNA, which forms our genes. These proteins are tumor suppressor (growth-inhibiting) genes. When defective, DNA cannot be repaired and cancer development begins through damaged DNA. When this main repair route fails, a second tumor cell repair pathway, polymerase (PARP), becomes more active. Suppressing PARP kills cancer cells, so drugs developed against this pathway form targeted treatment for patients with BRCA 1-2 mutations. Drugs in this group include Olaparib, Veliparib and Niraparib.

For ovarian cancer with damaged BRCA1-2 genes, FDA (United States Food and Drug Administration) approval in 2014 was granted to Olaparib (Lynparza) , which demonstrated similar success in studies of breast and prostate cancers with damaged BRCA1-2 genes. A study published in the prestigious NEJM included 49 patients with hormone-resistant prostate cancer.

All had received chemotherapy and all had DNA repair pathway damage (%50 had BRCA2 mutations). Compared with placebo (the group receiving no drug), olaparib provided an additional 6 months of overall survival. Although not yet FDA-approved for prostate cancer, it has become a promising drug for our patients.

Veliparib, in a phase II study presented at the 2016 American Cancer Congress (ASCO), included 153 hormone-resistant prostate cancer patients. It was added to abiraterone (zytiga), used for advanced prostate cancer. Regardless of DNA damage status, veliparib increased time to progression and reduced PSA (prostate-specific antigen). In the subgroup with damaged DNA repair proteins, success was greater, with an additional %45 contribution to disease response and a %90 PSA response. Veliparib also appears likely to have a future role for our advanced prostate cancer patients. Nirapanib , our PARP pathway inhibitor, remains under investigation.

In conclusion, although these drugs demonstrating targeted treatment success have not yet entered everyday practice, they offer promising treatment options for our patients.

Sources

Colin C. Pritchard, M.D., Ph.D., Joaquin Mateo, M.D., Michael F. Walsh, M.D.
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
N Engl J Med 2016; 375:443-453August 4, 2016DOI: 10.1056/NEJMoa1603144

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The Surprising Link Between BRCA Mutations and Prostate Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy